P-136 - ALTERNATIVE DOSING SCHEDULES FOR THERAPEUTIC WINDOW OPTIMIZATION FOR THE ATAXIA TELANGIECTASIA & RAD3-RELATED PATHWAY (ATR) INHIBITOR ELIMUSERTIB IN PATIENTS WITH ADVANCED SOLID TUMORS: M&S -BASED EXPLORATION USING PHASE I DATA.
Y. Zhang1, J. Hreiki2, G. Wilkinson1, B. Ploeger1; 1Bayer AG, Berlin, Germany, 2Bayer AG, Whippany, NJ, USA.
.png)